

CANNABIS INTELLIGENCE BRIEFING

Concentrates: The Hottest Product Category in Cannabis

Executive Summary



Concentrates: The Hottest Product Category in Cannabis

PUBLISHED BY



IN PARTNERSHIP WITH









Acknowledgements



05 Executive Summary The Rapid Rise of Concentrates

OB The Opportunity Concentrating Cannabis Profits

20 Extraction Methods: Get More Product from the Plant

26 Product Brands Bringing Branding Savvy to Cannabis Sales

34 Who Leading Industry Practices and Brands

THIS IS ONLY THE EXECUTIVE SUMMARY Order the full report at shop.bdsanalytics.com





Retail consumer appeal is propelling concentrates toward an estimated \$8 billion in retail sales by 2022, outpacing growth in traditional flower sales

Letter from the Editor

The reunion of technology and cannabis, after their 80year forced separation, has quickly yielded profitable results in the form of concentrates. A product category that was just 10% of legal sales in the United States in 2014, should amount to 27% of the market this year after just a few years of advancements in extraction technology, battery miniaturization and optimization, heating element development, and form-factor design.

In our forecast model, concentrates grow to nearly match flower sales, in the \$8-billion range, by 2022. If the pace of legalization quickens to move more states from limited, medical-only status to allow adult use, concentrates will more quickly exceed flower sales in legal states.

Of course, factoring in the immense illicit market that will likely remain flower-dominant. concentrates will still be a niche product five years hence. But there is clearly a growing consumer preference for vaping versus smoking that is also happening with tobacco consumption, and the concentrates revolution will affect every aspect of the legal cannabis business.

For consumers, it's a discreet and healthier choice that will likely make cannabis consumers of people who would never dream of inhaling smoke. That will cause the category to represent ever more retail display space, and likely spawn vape-only stores and on-premises consumption venues.

Concentrates will cut costs at every stage of the supply chain-every milligram of cannabinoids delivered to consumers as an extract is cheaper to distribute than as flower. But the main savings will be at the agriculture level, where expensive warehouse and greenhouse grows designed to provide pretty buds give way to traditional outdoor growing of a commodity crop. The cost savings-and broader consumer appeal of concentrates-will prove critical as the legal market struggles

> under the weight of heavy tax and regulatory loads to compete with the illicit market.



US Cannabis Spending by Category (In Billions)



Tom Adams Editor in Chief Arcview Market Research Managing Director **BDS** Analytics

THIS IS ONLY THE EXECUTIVE SUMMARY Order the full report at shop.bdsanalytics.com





ACKNOWLEDGEMENTS

PUBLISHER

Arcview Market Research in partnership with BDS Analytics

EDITOR IN CHIEF

Tom Adams

ANALYSTS

Brendan Mitchel-Chesebro Antonette Goroch Michael Arrington Brighton Hollis Maya Jasmin Laura Lee – Operations Manager

REPORT DESIGN

Martina Clary Micah Daigle

ADVISORS

Troy Dayton Roy Bingham David Abernathy Andrew Farley

SPECIAL THANKS

Cannabis Benchmarks [®] a division of New Leaf Data Services, LLC Chris Driessen- Organa Brands Robert Ferguson- Jetty Extracts Jordon Cloud Rahmil- Cura Cannabis Solutions Graham Sorkin- Evolab

DISCLOSURE

There are many companies mentioned in this report. Some of them are clients of The Arcview Group, BDS Analytics, and/or their officers and employees. In some cases, the publishers own minority stakes, warrants, or options in them. Neither Arcview nor BDS Analytics has received any compensation for coverage in this report. Since such a high percentage of companies in the sector are Arcview or BDS Analytics clients, it's part of what makes them most suited to have the deepest understanding of the markets.

METHODOLOGY

The foundation of GreenEdge[™] data is BDS Analytics' panel of participating dispensaries that contribute daily point of sales data. Dispensary panels are recruited to be both statistically significant as well as representative of the makeup of dispensaries in the market. Panel recruitment is ongoing and whenever possible, new participating dispensaries provide historic sales data that is incorporated into the data of record. As the underlying sample increases over time, historic data also undergoes changes that could impact category mix, brand/product share, and average retail prices. When conducting analysis, it is recommended to update the historic data in your comparisons rather than rely on previously downloaded information.

THIS IS ONLY THE EXECUTIVE SUMMARY





Order the full report at shop.bdsanalytics.com

The Rapid Rise of Concentrates

Cannabis concentrates have emerged as the fastest-growing of the three major segments of the legal cannabis market—flower, concentrates and edibles. BDS Analytics' GreenEdge point-of-sale tracking service data shows that consumers, particularly those in adult-use markets, are gravitating toward this stronger, discrete, portable product category. Retail consumer appeal is propelling concentrates toward an estimated

U.S. Legal Cannabis, Concentrates & Vape Sales 2014-2022 (In Billions)



Source: BDS Analytics' GreenEdge

Analytics

ARCVIEW

THIS IS ONLY THE EXECUTIVE SUMMARY

Order the full report at **shop.bdsanalytics.com**

\$8 billion in retail sales by 2022, outpacing growth in traditional flower sales. For the first time, concentrates are establishing a unique identity and retail subsectors.

When Colorado commenced legal adult sales in January 2014, the fledgling concentrates category made up just over 15% of the total, overshadowed by traditional flower's 69%. As adult-use legalization spread, largely due to the addition of the California market, that percentage has more than doubled to 26.6%, yielding a noteworthy \$2 billion in 2017 for all U.S. legal sales.

Much growth can be attributed to the beginner-friendly, brand-identified vaporizer cartridge subcategory. A once-overlooked category with sales of under \$100 million in 2014, cartridges now surpass the specialized subcategories of resins, waxes, etc. In 2017, vapes made up more than half of total U.S. concentrate sales, at just over \$1 billion. The subcategory's multifaceted appeal suggests this pattern will continue, with cartridges expected to garner nearly \$6.5 billion in total U.S. sales in 2022, almost 80% of concentrate dollar sales that year. Vaporizer product sales in Colorado, Washington and Oregon grew by 93% in 2017, the greatest gain by any concentrate product that year. This category was followed by live resin products, which grew by 67%, then oils at 43% growth. Wax and shatter remain substantial favorites, growing by 30% and 19% in 2017.

As the cartridge segment has grown, so have the footprints of multimarket brands. While expanding to markets in new states is often costly and can be unfruitful, it can bring huge top-line growth if efforts prove successful. Only two concentrate brands appear more than once in BDS Analytics's GreenEdge top-20 ranking of concentrate brands in California, Colorado, Oregon and Washington, but both of these brands were among the top five in brand share of dollar sales across all four



2017 vs 2016 % Growth by Product Subcategory: CO, WA, OR

THIS IS ONLY THE EXECUTIVE SUMMARY

Order the full report at **shop.bdsanalytics.com**





states. This illustrates just how early we are in the development of a national legal cannabis market. But ultimately, crossstate expansion will be a requirement for brands looking for long-term growth; hence expansion to new markets should be a top consideration for concentrate manufacturers once they achieve leadership positions in their home states.

Cross-state expansion will be a requirement for brands looking for long-term growth

THIS IS ONLY THE EXECUTIVE SUMMARY Order the full report at shop.bdsanalytics.com





Subscribe Today to the Cannabis Intelligence Briefing Series

Intelligent data and insights for the cannabis industry at your fingertips

Our annual subscribers receive:

- Every briefing as soon as it is released during the yearlong subscription
- The State of Legal Cannabis Markets, 7th Edition + Mid-Year Update
- Instant access to all historical intelligence reports

Briefings Available Today



Subscribe Today! shop.bdsanalytics.com





Visit shop.bdsanalytics.com to purchase individual reports for \$297 each or to subscribe to the Cannabis Intelligence Briefing Series for \$1,975. For questions, please contact info@bdsanalytics.com.

Cannabis, meet capital.

Prohibition is crumbling. Invest in what comes next.

197 **Funded Companies**







Arcview is the #1 source of deal flow in the fastest growing industry. If you qualify as a high net worth accredited investor or if you are an entrepreneur raising capital, Arcview might be right for you.



The leader in cannabis business intelligence and market share tracking

It's simple. We provide answers. You make more money.

We answer the WHO, WHAT, WHEN, WHERE, WHY, HOW MUCH, and WHAT'S NEXT in cannabis.

"BDS Analytics has been a great partner from Day 1. The retail data they provide our business helps us in so many ways. We're able to track trends, more smartly merchandise our dispensary, and just make better business decisions all-around."

Debby Goldsberry, Executive Director, Magnolia Wellness





Ready to build a successful cannabis business?

We recommend you subscribe to our industry-leading GreenEdge[™] Platform which powers our retail sales tracking data, unrivaled cannabis consumer research, and industry intelligence reports and services.

And for dispensaries across the US, we are actively recruiting GreenEdge dispensary partners in medical-only and adult-use markets.

Contact us today to learn more.

Just Released



The State of Legal Cannabis Markets, 7th Edition

The #1 cited market research for the cannabis industry, co-produced by Arcview Market Research and BDS Analytics



The report is a must-read for serious players in the cannabis industry looking for a competitive advantage. Featuring:

- You'll receive digital and hardbound versions of the 352 page report
- 178 data-rich charts and graphs/tables
- Downloadable slides of selected charts

"The depth and breadth of this report is unsurpassed and simply not available anywhere else."

Mark Passerini, Om of Medicine



THE WALL STREET JOURNAL As Seen In FORTUNE Forbes

Bloomberg

Get Yours Today!

Purchase at shop.bdsanalytics.com